BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
IVDs on the rise
Radiopharmaceuticals
Science '22 in Review
Top Biopharma Trends of 2022
Top Med-tech Trends of 2022
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, October 1, 2023
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» Antengene's Claudin 18.2 ADC ATG-022 awarded US orphan drug designations for gastric and pancreatic cancer
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Immuno-oncology
Antengene's Claudin 18.2 ADC ATG-022 awarded US orphan drug designations for gastric and pancreatic cancer
May 24, 2023
No Comments
Antengene Corp. Ltd.'s Claudin 18.2 antibody-drug conjugate (ADC) ATG-022 has been granted two orphan drug designations consecutively by the FDA for the treatment of gastric cancer and pancreatic cancer.
BioWorld Science
Cancer
Antibody-drug conjugate
Immuno-oncology
FDA
Orphan drug
